Cannabis may provide a treatment option for pulmonary fibrosis, according to a new study published by the journal Oncotarget and published online by the U.S. National Institute of Health.
According to Mayo Clinic, pulmonary fibrosis is “a lung disease that occurs when lung tissue becomes damaged and scarred. This thickened, stiff tissue makes it more difficult for your lungs to work properly.” As pulmonary fibrosis worsens, “you become progressively more short of breath.”
The study’s abstract begins by stating that; “Activation of cannabinoid receptor type 2 [something done naturally through cannabis consumption] has been shown to have anti-fibrosis function in skin and heart. However, whether activating cannabinoid receptor type 2 inhibits pulmonary fibrosis remains elusive.” In this study, researchers “aimed to investigate the role of cannabinoid receptor type 2 in pulmonary fibrosis in vitro and in vivo.”
After conducting their investigation, researchers found the data to indicate that “activating cannabinoid receptor type 2 by a pharmacological method might be a potential strategy for pulmonary fibrosis”.
About Anthony Martinelli
Anthony, co-founder and Editor-in-Chief of TheJointBlog, has worked closely with numerous elected officials who support cannabis law reform, including as the former Campaign Manager for Washington State Representative Dave Upthegrove. He has also been published by multiple media outlets, including the Seattle Times. He can be reached at TheJointBlog@TheJointBlog.com.